InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.
Stocks · News reference
8-K filing — InMed Pharmaceuticals Inc. (INM)
Filed: 2026-09-18 AccNo: 0001213900-26-101492 Size: 268 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading